KROSHIGH SIGNALOPERATIONAL10-K

KROS has shifted strategic focus from cardiovascular drug cibotercept to neuromuscular candidate rinvatercept while burning through nearly half its cash reserves.

The company appears to have discontinued or deprioritized its pulmonary arterial hypertension program (cibotercept) in favor of concentrating resources on Duchenne muscular dystrophy and ALS treatments. This pivot follows Phase 1 results announced in March 2025 and positions the company for a Phase 2 DMD trial in Q2 2026, but represents a significant strategic reallocation that could affect investor expectations about pipeline diversity and timelines.

Comparing 2026-03-04 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

KROS experienced substantial cash burn over the period, with cash and equivalents declining from $559.9M to $287.4M, reflecting the capital-intensive nature of clinical development. R&D expenses decreased meaningfully from $173.6M to $129.6M, likely reflecting the strategic refocus and potentially more efficient resource allocation toward the prioritized neuromuscular programs. The company maintains a strong balance sheet with reduced but manageable liabilities and sufficient cash runway for continued operations, though the burn rate will be critical to monitor given the upcoming Phase 2 trial initiation.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-48.7%
$559.9M→$287.4M

Cash declined 48.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Stockholders Equity
Balance Sheet
-47%
$571.6M→$303.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-46.4%
$588.9M→$315.4M

Current assets declined 46.4% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-45.1%
$615.9M→$338.0M

Total assets contracted 45.1% — asset sales, write-downs, or balance sheet optimization underway.

Accounts Receivable
Balance Sheet
+30.1%
$2.7M→$3.6M

Receivables surged 30.1% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Current Liabilities
Balance Sheet
-25.6%
$27.4M→$20.4M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
-25.3%
$173.6M→$129.6M

R&D spending cut 25.3% — could signal cost discipline or concerning reduction in innovation investment.

Total Liabilities
Balance Sheet
-21.3%
$44.3M→$34.9M

Liabilities reduced 21.3% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-04
PRIOR — 2025-02-26
ADDED
As of February 27, 2026, there were 19,717,533 outstanding shares of the registrant's common stock, par value $0.0001 per share.
We are a leader in understanding the role of the TGF- family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood.
Our lead product candidate, rinvatercept (KER-065), is being developed for the treatment of neuromuscular diseases.
We are developing rinvatercept for the treatment of Duchenne muscular dystrophy, or DMD and for the treatment of amyotrophic lateral sclerosis, or ALS.
In March 2025, we announced initial topline results from the Phase 1 clinical trial of rinvatercept in healthy adult volunteers.
We expect to commence a Phase 2 clinical trial of rinvatercept in patients with DMD in the second quarter of 2026.
We also plan to engage regulators on the design of a Phase 2 clinical trial of rinvatercept in patients with ALS in the second half of 2026.
In July 2025, we announced that the first patient was dosed in the placebo-controlled Phase 3 RENEW clinical trial in patients with very low-, low-, or intermediate-risk MDS, which we refer to as lower-risk MDS.
The dosing of the first patient triggered a $10 million milestone payment to us under the license agreement with Takeda.
Our strategy focuses on the role of members of the TGF- family of proteins in the development of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood.
REMOVED
As of February 20, 2025, there were 40,562,047 outstanding shares of the registrant's common stock, par value $0.0001 per share.
We are a leader in understanding the role of the TGF- family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue.
One of o ur product candidates, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders .
Our second product candidate, KER-065, is being developed for the treatment of neuromuscular diseases.
Cibotercept is designed to bind to and inhibit the signaling of TGF- ligands that stimulate the proliferation of vascular endothelial and smooth muscle cells and fibroblasts, including activin A, activin B and myostatin (GDF8).
We believe that cibotercept has the potential to increase the signaling of bone morphogenic protein, or BMP, pathways through this inhibition of activin A and activin B signaling, and consequently treat diseases such as PAH that are associated with reduced BMP signaling, including inactivating mutations in the BMP receptors.
We are developing cibotercept for the treatment of PAH and for the treatment of cardiovascular disorders.
We expect to present topline data from our Phase 2 clinical trial evaluating cibotercept in patients with PAH, which we refer to as the TROPOS trial, in the second quarter of 2025.
We announced the early termination of the TROPOS trial in January 2025, based on an ongoing safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Following completion of the TROPOS trial, we plan to evaluate the appropriate development strategy for cibotercept, including in PAH and other potential indications.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →